Press Releases
Lack of colitis side effect with CXD101 and nivolumab combination therapy in CAROSELL Phase II clinical trial of MSS CRC
Read MoreOxford, UK,21 October 2019 – Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients, today
Read MoreOxford, UK, 30th September 2019 – Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients,
Read MoreOxford, UK, 6 August 2019 – Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients,
Read MoreOxford, UK, 17 Jun 2019 – Celleron Therapeutics, a UK-based company developing personalised medicines for cancer patients, announced today approval
Read MoreOxford UK, 15 June 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today that
Read MoreOxford, UK, 22 May 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, participated in the
Read MoreOxford, UK, 16 April 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today the
Read MoreOxford, UK, 21 March 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announce today a
Read MoreOxford, UK, 16 March 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, held a cake
Read More